Fusion Pharmaceuticals Inc

NASDAQ:FUSN   12:24:36 PM EDT
3.86
+0.15 (+4.04%)
Regulatory, Earnings Announcements

Fusion Pharmaceuticals Announces First Quarter 2022 Financial Results And Clinical Program Updates

Published: 05/10/2022 11:15 GMT
Fusion Pharmaceuticals Inc (FUSN) - Fusion Pharmaceuticals Announces First Quarter 2022 Financial Results and Clinical Program Updates.
Phase 1 Data for Fpi-1434 Anticipated to Be Reported in Second Half of 2022.
Fusion Pharma - Advancing Additional Programs With Investigational New Drug Application Filing for Fpi-2059 Anticipated in Q2 of 2022.
Expect First Novel Tat Under Collaboration Agreement With Astrazeneca in Ind-enabling Studies.
Qtrly Loss per Share $0.46.
Q1 Earnings per Share View $-0.48 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0.18 Million
Adjusted EPS is expected to be -$0.51

Next Quarter Revenue Guidance is expected to be $0.17 Million
Next Quarter EPS Guidance is expected to be -$0.53

More details on our Analysts Page.